Status of Disease Burden of Lower Urinary Tract Symptoms in Chinese Male Community

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age40+
SponsorChinese PLA General Hospital

About this trial

This study, set up as a cross-sectional survey, seeks to delve into the disease burden and the demographic specifics of lower urinary tract symptoms (LUTS) among the male community in China. The investigators's main aim is to map out the overall and age-specific prevalence rates of LUTS within the Chinese male population. These insights are critical for understanding the public health dimensions of this condition. Moreover, the investigators plan to investigate several secondary aspects: the correlation of LUTS prevalence with factors like urbanization levels (rural vs. urban), geographical distribution, and lifestyle choices. Another significant focus will involve examining the treatment landscape for LUTS, looking at the portion of sufferers receiving treatment, the diversity in treatment durations, and the types of treatments employed (medication vs. surgery). This comprehensive analysis is intended to shed light on the prevailing management strategies for LUTS in China. The study is scheduled to unfold over 36 months and will comprise three pivotal phases: initial preparations, recruitment of subjects and collection of data, followed by the analysis of data and compilation of reports. The investigators will employ a range of methods such as questionnaires, physical exams, laboratory tests, imaging, and other medical evaluations to amass extensive data. This will allow the investigators to evaluate the prevalence of LUTS across various age groups among men and address the current gaps in epidemiological understanding.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Mainland China, aged 40 or older, male, in 31 provincial-level administrative regions.

Have resided for a total of 6 months or more in the survey county (district) in the past 12 months.

Normal communication, cooperation during physical examination, and good cognitive ability.

Willing to participate in and cooperate with this study, and sign the informed consent form.

Disqualifiers

Closed communities, such as armed forces and nursing homes.

Individuals with mental illnesses or other conditions that prevent cooperation.

Trial population

community sample

Trial design

Design model

Ecologic or community

Time perspective

Cross-sectional

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

International Prostate Symptom Score(IPSS)

A questionnaire to assess the condition of the prostate, report by score.The minimum value is 0, the maximum is 35, and the larger the score, the more severe the symptoms.

Time frame
DAY 1
2

Overactive Bladder Syndrome Score(OABSS)

A questionnaire to assess the condition of overactive bladder, report by score.The minimum value is 0, the maximum is 15, and the larger the score, the more severe the symptoms.The minimum value is 0, the maximum is 15, and the larger the score, the more severe the symptoms.

Time frame
Day 1
3

International Consultation on Incontinence Questionnaire - Short Form(ICIQ-SF)

Detection through urinary flow rate meter, report by score.The minimum value is 0, the maximum is 11, and the larger the score, the more severe the symptoms

Time frame
Day 1
4

Quality of Life Score(QOL)

t was used to assess the impact of lower urinary tract symptoms on quality of life, with a minimum score of 0 and a maximum score of 6. The smaller the score, the higher the quality of life.

Time frame
Day 1

Secondary outcomes

1

Prostatic volume

By transabdominal ultrasound, Prostatic volume (ml)= Lateral diameter of prostate(cm)\* Anterior and posterior prostatic diameter(cm) \* Diameter superior and inferior prostatic (cm) \*0.52

Time frame
Day 1
2

Maximum urinary flow rate

Detection through urinary flow rate meter (ml/min)

Time frame
Day 1
3

Residual urine

By transabdominal ultrasound (ml)

Time frame
Day 1
4

free prostatic specific antigen(fPSA)

ng/ml

Time frame
Day 1

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.